natgillin/translations-raw huggingface dataset:
The anti-Factor D antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable domain comprises: CDR-L1 having the amino acid sequence of SEQ ID NO: 16; CDR-L2 having the amino acid sequence of SEQ ID NO: 17; and CDR-L3 having the amino acid sequence of SEQ ID NO: 19, and the heavy chain variable domain comprises CDR-H1 having the amino acid sequence of SEQ ID NO: 13; CDR-H2 having the amino acid sequence of SEQ ID NO: 14; and CDR-H3 having the amino acid sequence of SEQ ID NO: 20. 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:5, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:17, a CDR3 je definiran sa SEQ ID NO:18; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:6, gdje je CDR1 definiran sa SEQ ID NO:13; CDR2 je definiran sa SEQ ID NO:14; i CDR3 je definiran sa SEQ ID NO:15;
The gate of triac 88, through the series diode 104-resistor 101, is positively biased during the positive half-wave of network 10 voltage on conductor 12. 
Gejt trijaka 88 je pozitivno napajan preko serijskog spoja diode 104, otpornika 101 za vrijeme pozitivne poluperiode napona mreže 10 na otporniku 12.
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, diC1-4alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, diC1-4alkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
receiving sequenced tags obtained from a random sequencing of DNA molecules contained in the biological sample, the biological sample being plasma, serum, saliva, or urine; 
Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je krv, plazma, serum, urin ili slina od trudnice.
In some embodiments, the polypeptides can exhibit higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin. 
Polipeptid prema bilo kojem od zahtjeva 8 do 13, naznačen time da polipeptid pokazuje viši afinitet vezanja za djelomično rascijepan fibrin nego afinitet vezanja za djelomično rascijepan fibrin mini-plazmina.
demapping the deinterleaved constellation values into cell words and to multiplex the demapped cell words into PLP data; bit-deinterleaving the multiplexed PLP data; LDPC-decoding the bit-deinterleaved PLP data; and 
Metoda iz patentnog zahtjeva 5 nadalje obuhvaća: raspletanje vremena-frekvencije konstelacijskih vrijednosti koje odgovaraju PLP podatku; demapiranje raspletenih konstelacijskih vrijednosti u stanične Tiječi; multipleksiranje demapiranih staničnih riječi u PLP podatke; raspletanje bitova multipleksiranih PLP podataka; LDPC-dekodiranje PLP podataka rspletenih bitova; 1
The product was filtered off and washed with isopropanol. 
Produkt je filtriran i opran s izopropanolom.
S-ketamine HCl; wherein the S-Ketamine HCl is present in an amount of about 161.4 mg/ml; 
(a) S-ketamin HCI; pri čemu se S-Ketamin HCI nalazi u količini od oko 161.4 mg/ml;
and R7 stand independently from each other for H, C3-C6 cycloalkyl, or halogen; 
R5 je fluor; R6 i R7 međusobno neovisno predstavljaju H, C3-Cg cikloalkil ili halogen;
These compositions apply in particular to compositions that have been reconstituted after lyophilisation, and the value of can be lower before lyophilisation and reconstitution (Figure 14). 
Ovi sastavi osobito se primjenjuju za sastave koji su se već rekonstituirali nakon liofilizacije, i vrijednost Tr može biti niža prije liofilizacije i rekonstitucije (Slika 14).
The compound of claim 6, wherein Ar2 is substituted or unsubstituted phenyl, thienyl, imidazolyl, pyridyl, or pyrazolyl. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time što Ar2 je supstituirani ili nesupstituirani fenil, tienil, imidazolil, piridil ili pirazolil.
A compound of claim 1 for use as a medicament for treating cells or tissues involved in a pathology characterized by dysfunctional neuronal cells caused by misregulation of the gene associated with the enzyme pantothenate kinase. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi kao medikament za liječenje neurodegeneracije kod subjekta povezane s pantotenat-kinazom.
is selected from hydrogen, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; 
alkila, supstituiranog ili nesupstituiranog C2-C;2 alkenila, 1 supstituiranog ili nesupstituiranog C2-C;2 alkinila;
The method according to claim 1, wherein the crosslinked hyaluronic acid of step a) is previously obtained from the crosslinking of a non-crosslinked hyaluronic acid with an effective amount of at least one crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, pustrescine, spermidine, spermine, and a mixture thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter.
The composition of claim 1, wherein said single-stranded RNAs or mRNAs encodes at least one protein selected from the group consisting of: IL-4; IL-13; IL-10; inducible nitric oxide synthase (iNOS); a heat shock protein; and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). 
Obrađeni sastav ribonukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što navedeni sastav ribonukleinske kiseline ili ssRNA ili mRNA kodira najmanje jedan protein odabran iz skupine koja se sastoji od:
In one embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 2 a heavy chain variable region CDR2 of SEQ ID NO: 16; a heavy chain variable region CDR3 of SEQ ID NO: 30; a light chain variable region CDR1 of SEQ ID NO: 44; a light chain variable region CDR2 of SEQ ID NO: 58; and a light chain variable region CDR3 of SEQ ID NO: 72. 
(b) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 2; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 16; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 30; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 44; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 58; i CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 72;
The device according to claim 1, wherein the perforated sheet comprises a plurality of rectangular shaped holes. 
Uređaj sukladno zahtjevu 1, gdje perforirani list sadrži veći broj pravokutno oblikovanih rupa.
A transmitter for transmitting broadcasting data to a receiver, the transmitter comprising: 
Metoda za prijenos emitiranog signala, metoda obuhvaća:
DEVICE, according to one or more of the previous claims, characterised in that the flashing of the indicator light of the receiver element (19) is synchronised with that of the transmitter element (3), by sending a sequence of infrared pulses, with at least two transmission frequencies. 
Mehanizam prema jednom ili više od prethodnih zahtjeva, naznačen time da se bljeskanje dojavnog svjetla prijemnika (4) sinkronizira s onim odašiljača (3) tako što se s najmanje dvije prijenosne frekvencije odašilje niz infracrvenih impulsa.
providing an apparatus comprising a receptacle for holding the exchangeable capsule, a fluid dispensing device for supplying an amount of fluid, such as water, under a pressure of at least six bars to the exchangeable capsule, and an outlet which, in use is in fluid communication with the capsule for draining the prepared beverage form the capsule and supplying the beverage to a container such as a cup; 
pripremanje naprave koja obuhvaća posudu za držanje zamjenjive kapsule, uređaj za istakanje tekućine za dostavu količine tekućine, primjerice vode, pod tlakom od najmanje 6 bara u zamjenjivu kapsulu, i jedan ispusni otvor koji je prilikom uporabe u tekućoj komunikaciji s kapsulom, u svrhu cijeđenja pripremljenog pića iz kapsule i dostavu pića do spremnika, primjerice šalice;
wherein the optional substituents for the optionally substituted 5- or 6-membered ring are selected from a group R8. 
naznačeno time što se opcijski supstituenti za opcijski supstituirane petero- ili šesteročlane prstenove odabiru iz skupine R8.
Method for treating solid and liquid wastes, characterized in that it is performed through a plant according to any one of the previous claims, said method providing a pyrolysis treatment of said solid and liquid wastes, from which a synthesis gas and an inert residual are obtained, said method comprising the steps of subjected to fractioned distillation the pyrolysis products, and sending to a new pyrolysis cycle the bituminous residuals of said fractioned distillation, said solid wastes comprising plastic materials and biomasses and being loaded directly into the pyrolysis chamber (2) in which they are subjected to said pyrolysis treatment, said liquid wastes comprising spent oils and greases which are inserted in said pyrolysis chamber (2) after mixing with said bituminous residuals coming from the fractioned distillation of the pyrolysis products. 
Postupak za obradu krutog i tekućeg otpada, naznačen time što se izvodi kroz postrojenje sukladno bilo kojem od prethodnih patentnih zahtjeva, navedeni postupak osiguravanja obrade pirolizom navedenih krutog I tekućeg otpada, iz kog se dobivaju sintezni plin i inertni ostatak, navedeni postupak obuhvaća korake podvrgavanja frakcioniranoj destilaciji proizvoda pirolize, i slanje u novi ciklus pirolize bitumenskih ostataka navedene frakcionirane destilacije, navedeni kruti otpadi sadrže plastične materijale i biomase 1 ubacuju se izravno u komoru (2) za pirolizu u kojoj se podvrgavaju spomenutoj obradi pirolizom, navedeni tekući otpadi obuhvaćaju korištena ulja i plinove koji se ubacuju u navedenu komoru (2) za pirolizu poslije miješanja s navedenim bitumenskim ostacima koji izlaze iz frakcionirane destilacije proizvoda pirolize.
Preferred non-crystallising sugars or non-crystallising sugar alcohols include non-crystallising forms (or mixtures) of sorbitol, xylitol, maltitol, mannitol, and isomalt. 
Poželjni ne-kristalizirajući šećeri ili ne-kristalizirajući šećerni alkoholi obuhvaćaju ne-kristalizirajuće oblike (ili smjese) sorbitola, ksilitola, maltitola, manitola i izomaltitol.
The methanolic solution of the dicarboxylic acid 10 obtained in step D was cooled at 0-5° C. and 100 ml thionyl chloride was added dropwise. 
Otopina dikarboksilne kiseline 10 u metanolu dobivena u koraku D ohladi se pri 0 - 5 *C 1 postepeno se doda 100 ml tionil klorida.
A combination for use according to claim 3 or 4, wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
In embodiments of the invention, the active compound or a salt can be administered in combination with another antiviral agent such as ribavirin, another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. 
Primjena prema patentnom zahtjevu 15, naznačena time što je antivirusni spoj izabran iz grupe koju čine inhibitor HCY proteaze, drugi nukleozidni inhibitor HCV polimeraze, ne-nukleozidni inhibitor HCV polimeraze, inhhibitor HCY helikaze, inhibitor HCV primaze i inhibitor HCY fuzije.
The antisense oligomer according to paragraph 1, which is an oligonucleotide. 
2. | Antisensni oligomer u skladu s patentnim zahtjevom 1, koji je oligonukleotid.
The in vitro diagnostic of any one of items 1 to 13 wherein said patient has a risk factor for endometrial cancer or is being screened for endometrial cancer. 
Postupak dijagnosticiranja in vitro u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što navedena pacijentica posjeduje čimbenik rizika od pojave rake endometrija ili prolazi pretrage na rak endometrija.
A single immunoglobulin variable domain antibody according to any one of claims 1-11 for use in a method of treating, alleviating or preventing an autoimmune disease or a graft-related disease, preferably a disease selected from the group consisting of an allograft rejection, a xenograft transplant rejection, graft versus host disease, systemic lupus erythematosis, Sjogren's syndrome, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and lupus nephritis. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom prema bilo kojem od patentnih zahtjeva 1-11 za primjenu u metodi liječenja, ublažavanja ili sprečavanja autoimune bolesti ili bolesti u vezi sa kalemom, poželjno bolesti odabrane iz grupe koja se sastoji od odbacivanja alografta, odbacivanja transplantata ksenografta, bolesti presatka protiv domaćina, sistemskog eritematoznog lupusa, Sjogrenovog sindroma, multiple skleroze, reumatoidnog artritisa, dijabetesa, psorijaze, skleroderme, ateroskleroze, upalne bolesti crijeva, Kronove bolesti, ulceroznog kolitisa, i lupus nefritisa.
An impact attenuator according to claim 10, wherein the progressively increasing braking action is achieved in that the draw element has an increasing width in opposite direction in relation to the movement of the draw element in relation to the housing. 
Prigušivač udara prema zahtjevu 10, naznačen time da se progresivno povećanje djelovanja kočenja postiže time da duguljasti izvlačivi element (14) ima povećanu širinu u suprotnom smjeru u odnosu na pomicanje duguljastog izvlačivog elementa u odnosu na kućište (10).
Preferably, the intestinal disorder is selected from irritable bowel syndrome (IBS), inflammatory bowel disorder (IBD), functional dyspepsia, functional constipation, functional diarrhoea (including antibiotic associated diarrhoea, traveller's diarrhoea and pediatric diarrhoea), functional abdominal pain, functional bloating, Epigastric Pain Syndrome, Postprandial Distress Syndrome, Crohn's disease, ulcerative colitis, gastrointestinal reflux disease (GERD), allergies, atopic diseases e.g. atopic dermatitis, necrotising enterocolitis, other infections, and combinations thereof. 
Jedan ili više bakterijskih sojeva mliječne kiseline prema zahtjevu 6, naznačen time da je crijevni poremećaj salmoneloza, sindrom iritabilnog crijeva (IBS), upalni crijevni poremećaj (IBD), funkcionalna dispepsija, funkcionalna konstipacija, funkcionalna dijareja (uključujući dijareju koja je povezana s antibioticima, dijareju povezanu s putovanjem u pedijatrijsku dijareja), funkcionalna bol u trbuhu, funkcionalna nadutost, sindrom epigastrične boli, postprandijalni distres sindrom, Crohnova bolest, ulcerozni kolitis, nekrotizirajući enterokolitis, te njihove kombinacije.
Asparagine at a concentration ranging from about 810 to about 850 mg/L, most preferably about 830. 
-Asparagin u koncentraciji u rasponu od oko 810 do oko 850 mg/L, najpoželjnije oko 830.
For example, bonding spots may have a circular, rectangular or other cross-section. 
Na primjer, točke spajanja mogu imati kružni, pravokutan ili ncki drugi poprečni presjek.
Other suitable pharmaceutically or dietarily acceptable carriers or excipients include water, mineral oil, ethylene glycol, propylene glycol, lanolin, glyceryl stearate, sorbitan stearate, isopropyl myristate, isopropyl palmitate, acetone, glycerine, phosphatidylcholine, sodium cholate and ethanol, but are not limited thereto. 
Sredstvo sukladno patentnom zahtjevu 1, naznačeno time, da se farmaceutski prihvatljivi ekscipijenti 1/1 nosači biraju između vode, minerala ulja, etilen glikola, propilen glikola, lanolina, gliceril stearata, sorbitan stearata, izopropil miristata, izopropila, palmitata, acetona, glicerina, fosfatidikolim, natrijev kolat i etanol.
when L1 represents hydrogen, reacting a compound of formula (II), or a salt thereof, wherein LG1 represents a leaving group and L, L2, L3, L4, R1, m, n, V, W, X, Y and Z are as defined in formula (I), with a compound of formula (III), or a salt thereof, wherein Ar is as defined in formula (I) and P1* is hydrogen or a protective group in the presence of a base, followed by removal of the protective group; or 
HR P20120968 T1 Ar (LT) gdje Ar je kako je definirano u formuli (I) i P!" je vodik ili zaštitna skupina u prisutnosti baze, nakon čega slijedi uklanjanje zaštitne skupine; ili kada L' predstavlja vodik, od reakcije spoja sa formulom (IV), ili njegove soli,
A pharmaceutical composition comprising: an HDAC inhibitor, wherein the HDAC inhibitor is a compound of the following formula or pharmaceutically acceptable salt or solvate thereof: and arginine. 
(a) HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom, ili njegov(a) farmaceutski prihvatljiva sol ili solvat: i (b) arginin.
the composition being reconstituted with about 5 ml of water for injection. In this composition the total amount of sodium content of the ceftriaxone sodium and the sulbactam sodium is about 66.15 mg with 2.87 mEq of sodium. 
(6) EDTA u količini od 0.5 mg, spomenuta smjesa je rekonstituirana sa 5 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 66.15 mg, uz 2.87 mEq natrija.
The process according to any one of claims 1 to 12, wherein said mineral pigment material is selected from calcium carbonate, calcium carbonate containing minerals, mixed carbonate based fillers, or mixtures thereof, and wherein the calcium carbonate containing minerals preferably comprise dolomite, and the mixed carbonate based fillers are preferably selected from calcium associated with magnesium, clay, talc, talc-calcium carbonate mixtures, calcium carbonate-kaolin mixtures, or mixtures of natural calcium carbonate with aluminium hydroxide, mica or with synthetic or natural fibers or co-structures of minerals, preferably talc-calcium carbonate or talc-titanium dioxide or calcium carbonate-titanium dioxide co-structures. 
Postupak prema bilo kojem od zahtjeva 1 do 12, gdje se mineralni pigmentni materijal izabire između kalcijevog karbonata, minerala koji sadrže kalcijev karbonat, miješanih punila na bazi karbonata, ili njihovih smjesa, pri čemu minerali koji sadrže kalcijev karbonat poželjno obuhvaćaju dolomit, i miješana punila na bazi karbonata se poželjno izabiru između kalcija povezanog s magnezijem, gline, talka, smjesa talka 1 kalcijevog karbonata, smjesa kaolina i kalcijevog karbonata, ili smjesa prirodnog kalcijevog karbonata s aluminijevim hidroksidom, tinjcem (mica) ili sa sintetičkim ili prirodnim vlaknima ili ko-strukturama minerala, poželjno ko-strukture talk-kalcijev karbonat ili talk-titanijev dioksid ili kalcijev karbonat-titanijev dioksid.
The method of embodiment 3 or embodiment 4, wherein the determining step comprises: retrieving an IMSI list from the HLR for the subscribed device, the IMSI list comprising all of the IMSIs which are allocated to the subscribed device; and determining if the IMSI list comprises an IMSI which is appropriate for the current location of the subscribed device. 
Postupak prema zahtjevu 3 i zahtjevu 4 pri čemu korak određivanja obuhvaća: dobivanje IMSI liste od HLR-a za pretplatnički uređaj, pri čemu IMSI lista obuhvaća sve IMSI-je koji su pridruženi pretplatničkom uređaju; 1 određivanje da li IMSI lista obuhvaća IMSI koji je odgovarajući za trenutnu lokaciju pretplatničkog uređaja.
A citrate salt of formula I: 
Citratna sol formule I ili njezin hidrat: o
A compound according to claim 1, wherein each of R1 and R′1, or said fused ring structure formed thereby, is optionally substituted by at least one substituent selected from the group consisting of: fluorine and chlorine atoms, hydroxy groups, linear or branched alkoxy groups containing from 1 to 5 carbon atoms, linear or branched alkyl groups containing from 1 to 5 carbon atoms, trifluoromethyl and trifluoromethoxy groups, and —CN groups, and wherein, when there is more than one substituent, then each said substituent is the same or different. 
Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R, 1 R',, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine koja sadrži: atome fluora ili klora, hidroksi skupine, ravne ili razgranate alkoksi skupine koje sadrže od 1 do 5 atoma ugljika, ravne ili razgranate alkilne skupine koje sadrže od 1 do 5 atoma ugljika, trifluorometil i trifluorometoksi skupine, i -CN skupine, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit,
A method according to claim 12 or claim 13 wherein the GPR119 agonist is an agonist of human GPR119. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je selektivni GPR119 agonist.
EPMATHMARKEREP denoting the bitrate of B frames computed per scene; 
B5, koji označuje brzinu bitova B kadrova izračunatih po sceni;
is selected from the group consisting of hydrogen and C1-4alkyl; and 
je odabran od vodika i C1-4alkila; i
The composition according to claim 8, wherein the plasticizer is polyethylene glycol. 
Pripravak u skladu sa zahtjevom 6, naznačen time, da je plastifikator polietilen glikol.
A pharmaceutical composition comprising an isolated antibody that comprises a heavy chain variable domain sequence comprising SEQ ID NO:3 and a light chain variable domain sequence comprising SEQ ID NO:4, and wherein said antibody specifically binds human IL-17 receptor A, for use in a method of treating psoriasis in an adult or juvenile patient having psoriasis, wherein the method comprises administering to said patient the pharmaceutical in a single or divided dose of about 70 to about 300 mg antibody per dose administered at time "0" (the first administration), at one week post time "0", and then administered every two weeks following the week one administration. 
Farmaceutska formulacija, koja sadrži vodenu otopinu pufera glutaminske kiseline i protutijela koje sadrži sekvencu varijabilne domene teškog lanca koja obuhvaća SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja obuhvaća SEQ ID NO:4, naznačena time da se navedeno protutijelo specifično veže na ljudski receptor A za IL-17, te što:
Branched-species are expected to increase the rigidity of the structure more per unit molecular weight gain than are straight-chain species. 
Za razgranate grupe očekuje se da više povećavaju krutost strukture po jedinici molekulske mase od ravnolančanih vrsta.
PLAVIX is administered orally. The recommended oral dose of PLAVIX is 75 mg once daily. 
On se primjenjuje oralno, a preporučena je oralna doza 75 mg jednom dnevno..